Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Using a novel gene signature for predicting the efficacy of the transarterial chemoembolization in patients with hepatocellular carcinoma.

ABSTRACT: Using a novel gene signature for predicting the efficacy of the transarterial chemoembolization in patients with hepatocellular carcinoma.

PROVIDER: PRJNA413131 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Finding Sorafenib-Responding Signature in Hepatocellular Carcinoma (HCC)

Project description:Sorafenib has been a cornerstone in hepatocellular carcinoma (HCC) therapy; however, its efficacy is limited, and identifying patients that will respond to sorafenib is challenging. Gene expression data from 33 HCC tumors treated with sorafenib were analyzed to construct a prediction model aimed at identifying patients with greater benefit from sorafenib treatment. The analysis of transcriptome data revealed a 50-gene signature, KUSS50 (Korea University Sorafenib Signature with 50 genes), that exhibited high predictive power in identifying patients responded to sorafenib treatment in a training cohort. Extensive validation across 2 independent cohorts (IMbrave150 and BIOSTORM) given sorafenib demonstrated KUSS50's high specificity in predicting sorafenib response. Genomic analyses identified distinct molecular characteristics linked with KUSS50 subtypes, including an increased mutation rate and activation of ferroptosis, suggesting increased baseline ferroptotic activity in HCCs, which may sensitize them to sorafenib. The benefit subtype also overlapped with those in previously defined genomic HCC subtypes associated with stemness and aggressiveness. Conversely, the non-benefit subtype correlated with -catenin mutations and increased tumor purity, underscoring the biological significance of the signature. In conclusion, KUSS50 is a clinically actionable biomarker for optimizing HCC patient selection for treatment with sorafenib, providing an opportunity to improve outcomes. Further exploration of KUSS50's underlying biology, particularly the involvement of ferroptosis in sorafenib sensitivity, could provide additional therapeutic insights.

2025-12-31 | GSE285625 | GEO

Integrated analysis of the anoikis-related signature identifies RAC3 as a novel therapeutic target in hepatocellular carcinoma

Project description:Introduction: Anoikis is a form of programmed cell death. Anoikis resistance in hepatocellular carcinoma (HCC) promotes cancer cells shedding from the primary tumor site, thus contributing to survival and distant metastasis. However, the prognostic significance of anoikis-related genes (ARGs) and the biological functions of crucial genes in HCC have not been reported. Objectives: This study aimed to construct a model for predicting the outcome of patients with HCC based on ARGs and to investigate the clinicopathological significance and function of Rac family small GTPase 3 (RAC3) in HCC.

2025-05-07 | PXD057450 | Pride

Finding Sorafenib-Responding Signature in Hepatocellular Carcinoma (HCC)

Project description:Finding Sorafenib-Responding Signature in Hepatocellular Carcinoma (HCC)

| PRJNA1204978 | ENA

Project description:Hepatocellular carcinoma (HCC) is the most common form of liver cancer and a major cause of cancer-related deaths worldwide. Nevertheless, treatment and prognosis are still dependent on clinical and pathological factors, given that molecular biomarkers predicting survival outcomes are lacking. The extensive molecular heterogeneity characterizing HCC is denoted by the large number of signaling pathways involved in tumor initiation and progression. Among these, aberrant activation of the Wnt/-catenin pathway is the most frequent alteration. Various mechanisms can contribute to signaling hyperactivation, including somatic mutations and epigenetic alterations. Here, we have identified a Wnt/-catenin-related transcriptional signature denoting hyperactivated pathway signaling regardless of the presence of pathway-related activating mutations. The WNT signature predicts survival outcomes in two independent HCC patient cohorts and is associated with distinctive immunogenomic features denoting immune exclusion.

2026-07-01 | GSE270897 | GEO

Gene Signature to Identify Vascular Invasion in Human Hepatocellular Carcinoma

Project description:This SuperSeries is composed of the following subset Series: GSE9843: Gene expression profiling of 91 hepatocellular carcinomas with hepatitis C virus etiology, Samples with "vascular invasion: Yes/No" were included in the study. GSE20017: Gene Signature to Identify Vascular Invasion in Hepatocellular Carcinoma Refer to individual Series

2011-07-30 | E-GEOD-20238 | biostudies-arrayexpress

A five-microRNA-signature predicting recurrence in HNSCC

Project description:The risk of locoregional or distant failure in advanced HPV-negative head and neck squamous cell carcinoma (HNSCC) patients is high. However, no suitable markers for stratification are clinically available. Thus, we aimed to identify a microRNA(miRNA)-signature predicting disease recurrence. For this purpose the miRNA profiles from 162 HNSCC samples were analysed with regard to identification of a low-complex porgnostic signature. The data set consists of a discovery dataset (n=85) and a validation dataset (n=77). The study resulted in a prognostic 5-miRNA signature significantly predicting the relevant clinical endpoint freedom from recurrence.

2018-09-06 | E-MTAB-5793 | biostudies-arrayexpress

A novel genomic signature predicting FDG uptake in diverse metastatic tumors

Project description:A novel genomic signature predicting FDG uptake in diverse metastatic tumors

| PRJNA421282 | ENA

Integrated analysis of the anoikis-related signature identifies RAC3 as a novel therapeutic target in hepatocellular carcinoma

2025-03-26 | GSE273947 | GEO

Molecular Signature of Hepatitis D Virus-Associated Hepatocellular Carcinoma

Project description:Molecular Signature of Hepatitis D Virus-Associated Hepatocellular Carcinoma

| PRJNA419216 | ENA

A genomic enhancer signature associates with Hepatocellular Carcinoma prognosis

Project description:A genomic enhancer signature associates with Hepatocellular Carcinoma prognosis

| PRJNA875090 | ENA